4Tissue

4Tissue is a private, pre-revenue biotech company pioneering a proprietary bioresorbable hydrogel platform for regenerative medicine. Its lead program, Tissurel®, is a first-in-class injectable designed for breast reconstruction that protects and nurtures a patient's own fat or stem cells to generate durable, natural tissue. The company, founded in 2016 by leading academic surgeons and polymer scientists, is addressing a critical unmet need in oncology by aiming to simplify reconstructive surgery and improve patient outcomes with a single, minimally invasive treatment.

Proprietary toolbox of biocompatible, bioresorbable polymers processed into hydrogels, injectables, and 3D-printed implants. The core technology protects and nurtures transplanted cells (e.g., adipose-derived cells) to enhance survival and promote natural tissue regeneration as the hydrogel resorbs.

Competes against traditional silicone implants (e.g., Allergan, Mentor) and autologous flap surgeries, as well as emerging techniques in fat grafting and tissue engineering. Other biotech firms are developing supportive scaffolds for regenerative procedures, but 4Tissue's specific injectable hydrogel approach is differentiated.